MA41517A - Neutralisation du virus du chikungunya à médiation par des anticorps - Google Patents

Neutralisation du virus du chikungunya à médiation par des anticorps

Info

Publication number
MA41517A
MA41517A MA041517A MA41517A MA41517A MA 41517 A MA41517 A MA 41517A MA 041517 A MA041517 A MA 041517A MA 41517 A MA41517 A MA 41517A MA 41517 A MA41517 A MA 41517A
Authority
MA
Morocco
Prior art keywords
neutralization
mediated
antibody
chikungunya virus
chikungunya
Prior art date
Application number
MA041517A
Other languages
English (en)
Inventor
James E Crowe
Terence Dermody
Laurie Silva
Scott A Smith
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of MA41517A publication Critical patent/MA41517A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/181—Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE or semliki forest virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
MA041517A 2015-04-14 2016-04-13 Neutralisation du virus du chikungunya à médiation par des anticorps MA41517A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562147354P 2015-04-14 2015-04-14

Publications (1)

Publication Number Publication Date
MA41517A true MA41517A (fr) 2017-12-19

Family

ID=57126199

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041517A MA41517A (fr) 2015-04-14 2016-04-13 Neutralisation du virus du chikungunya à médiation par des anticorps

Country Status (28)

Country Link
US (2) US10787503B2 (fr)
EP (1) EP3283101A4 (fr)
JP (3) JP6979875B2 (fr)
KR (2) KR20230087616A (fr)
CN (2) CN107708726B (fr)
AR (1) AR104264A1 (fr)
AU (2) AU2016250188C1 (fr)
BR (1) BR112017021952A2 (fr)
CA (2) CA3176525A1 (fr)
CL (1) CL2017002596A1 (fr)
CO (1) CO2017010316A2 (fr)
CR (2) CR20170518A (fr)
DO (1) DOP2017000236A (fr)
EA (1) EA037060B1 (fr)
EC (1) ECSP17075750A (fr)
HK (1) HK1246671A1 (fr)
IL (2) IL290449B2 (fr)
MA (1) MA41517A (fr)
MX (2) MX2017013286A (fr)
MY (1) MY191666A (fr)
NZ (1) NZ736445A (fr)
PE (2) PE20220297A1 (fr)
PH (1) PH12017501865A1 (fr)
SG (2) SG11201708152SA (fr)
TN (1) TN2017000438A1 (fr)
TW (2) TW202248210A (fr)
UA (1) UA125206C2 (fr)
WO (1) WO2016168417A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11286295B2 (en) 2016-10-20 2022-03-29 Sanofi Anti-CHIKV monoclonal antibodies directed against the E2 structural protein
KR102029394B1 (ko) * 2017-11-14 2019-10-07 재단법인 바이오나노헬스가드연구단 치쿤구니아 바이러스 감염 진단용 단일클론항체, 이를 생산하는 하이브리도마 및 이를 이용한 치쿤구니아 바이러스 감염 진단 방법
WO2019136241A1 (fr) 2018-01-05 2019-07-11 Modernatx, Inc. Polynucléotides codant pour des anticorps anti-virus du chikungunya
US11851478B2 (en) 2018-01-05 2023-12-26 Vanderbilt University Antibody-mediated neutralization of chikungunya virus
JP6906207B2 (ja) * 2018-02-09 2021-07-21 国立大学法人大阪大学 チクングニアウイルス検出用免疫クロマト分析装置
JP7359390B2 (ja) * 2018-02-09 2023-10-11 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
WO2019236875A1 (fr) * 2018-06-06 2019-12-12 Albert Einstein College Of Medicine, Inc. Anticorps ou fragments d'anticorps de ceux-ci ciblant des alphavirus, et compositions et procédés les comprenant
US20230065377A1 (en) * 2019-08-31 2023-03-02 Vanderbilt University Human antibodies to alphaviruses
KR102202082B1 (ko) * 2019-09-25 2021-01-11 충북대학교 산학협력단 치쿤군야 바이러스의 외피단백질 도메인 ⅱ에 대해 특이적으로 결합하는 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
CN110922478B (zh) * 2019-12-07 2021-07-30 中国人民解放军军事科学院军事医学研究院 针对特异表位的抗基孔肯雅热的全人源单克隆抗体及应用
WO2022101805A1 (fr) * 2020-11-13 2022-05-19 Emergent Biosolutions Canada Inc. Globulines hyperimmunes pour le traitement d'infections par le virus chikungunya

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2598966A1 (fr) 2007-09-07 2009-03-07 Institut Pasteur Anticorps monoclonaux du chikungunya et leurs utilisations
WO2010014854A2 (fr) * 2008-07-31 2010-02-04 The Regents Of The University Of California Anticorps neutralisant des neurotoxines botuliniques
WO2011124635A1 (fr) 2010-04-07 2011-10-13 Humalys Molécules de liaison au virus du chikungunya et leurs utilisations
EP3021868A4 (fr) * 2013-07-19 2017-03-01 Integral Molecular, Inc. Anticorps dirigés contre le virus chikungunya et leurs utilisations
US11286295B2 (en) * 2016-10-20 2022-03-29 Sanofi Anti-CHIKV monoclonal antibodies directed against the E2 structural protein

Also Published As

Publication number Publication date
AU2016250188B2 (en) 2022-02-03
AR104264A1 (es) 2017-07-05
AU2016250188A1 (en) 2017-11-02
US11345743B2 (en) 2022-05-31
NZ736445A (en) 2023-06-30
EA201792220A1 (ru) 2018-03-30
CL2017002596A1 (es) 2018-05-18
TW202248210A (zh) 2022-12-16
CN114478756A (zh) 2022-05-13
US20200277359A1 (en) 2020-09-03
KR102541905B1 (ko) 2023-06-12
BR112017021952A2 (pt) 2018-07-10
KR20180004403A (ko) 2018-01-11
DOP2017000236A (es) 2017-12-15
MX2017013286A (es) 2018-06-19
IL254891A0 (en) 2017-12-31
CA2982491C (fr) 2023-08-29
TW201643189A (zh) 2016-12-16
CA3176525A1 (fr) 2016-10-20
EP3283101A2 (fr) 2018-02-21
JP2022174144A (ja) 2022-11-22
SG11201708152SA (en) 2017-11-29
PH12017501865A1 (en) 2018-03-05
KR20230087616A (ko) 2023-06-16
EA037060B1 (ru) 2021-02-01
EP3283101A4 (fr) 2019-01-16
UA125206C2 (uk) 2022-02-02
JP2018520334A (ja) 2018-07-26
IL290449B2 (en) 2024-04-01
WO2016168417A2 (fr) 2016-10-20
JP2021144047A (ja) 2021-09-24
IL290449B1 (en) 2023-12-01
JP6979875B2 (ja) 2021-12-15
US10787503B2 (en) 2020-09-29
TWI772257B (zh) 2022-08-01
IL290449A (en) 2022-04-01
MX2021013207A (es) 2021-12-10
US20180079802A1 (en) 2018-03-22
TN2017000438A1 (en) 2019-04-12
MY191666A (en) 2022-07-06
CN107708726B (zh) 2022-01-14
CN107708726A (zh) 2018-02-16
CO2017010316A2 (es) 2017-12-15
PE20220297A1 (es) 2022-03-07
ECSP17075750A (es) 2018-02-28
AU2022202819A1 (en) 2022-05-19
AU2016250188C1 (en) 2022-08-11
PE20180171A1 (es) 2018-01-22
IL254891B (en) 2022-03-01
CR20170518A (es) 2018-01-25
CA2982491A1 (fr) 2016-10-20
SG10202107295XA (en) 2021-08-30
HK1246671A1 (zh) 2018-09-14
CR20210438A (es) 2021-10-04
WO2016168417A3 (fr) 2017-01-05

Similar Documents

Publication Publication Date Title
MA41517A (fr) Neutralisation du virus du chikungunya à médiation par des anticorps
DK3433368T3 (da) Transreplikerende rna
MA42134A (fr) Conjugués peptides/oligonucléotides
DK3400291T3 (da) Manipuleret virus
DK3609529T3 (da) Rna til behandling af autoimmune sygdomme
MA44006A (fr) Inhibiteur pde1
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
MA50657A (fr) Formulations de niraparib
DK3463269T3 (da) Hånddesinfektionsmiddel
DK3262411T3 (da) Antibody-mediated neutralization of marburg virus
MA44987A (fr) Formulations de médicaments améliorées
DK3408265T3 (da) Terapeutiske forbindelser
DK3280447T3 (da) Farmaceutiske formuleringer
MA50068A (fr) Formulations de copanlisib
DK3512518T3 (da) Buprenophinformuleringer med langvarig frigivelse
DK3329004T3 (da) Terapeutiske oligonukleotider
DK3302499T3 (da) Behandling af mitokondrielle sygdomme
DK3288967T3 (da) Farmaceutisk forbindelse
FR3039391B1 (fr) Orthese de contention
UA36458S (uk) Спіраль внутріматочна кільцеподібна
ES1189583Y (es) Conjunto asistencial
FI11313U1 (fi) Kertakäyttösytyke
IT201700033831U1 (it) Segnariga
DK3399899T3 (da) Håndholdt endoskop
UA36457S (uk) Песарій кільцеподібний